secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2025-10-03T23:59:59+00:00
Accession:  0001171843-25-006260
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience gets 180-day Nasdaq bid-price extension, transfers to Capital Market
--------------------------------------------------------------------------------

- Nasdaq granted until March 30, 2026 to reach $1.00 minimum bid price for 10 consecutive days.
- Common stock transferred from Nasdaq Global Market to Capital Market effective October 3, 2025; ticker HBIO remains.
- Company previously disclosed deficiency in April 2025 when bid price fell below $1.00 for 30 consecutive days.
- If compliance not met by March 30, 2026, delisting proceedings may begin; Company may consider a reverse stock split.
- No assurance of regaining compliance; Company will monitor closing bid price and evaluate options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325006260/0001171843-25-006260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325006260/f8k_100225.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-006260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer